Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Motixafortide for Hematopoietic Stem and Progenitor Cell Mobilization and Collection in Sickle Cell Disease

Alexis Kristine Leonard, Akshay Sharma, Yogindra Persaud, Parul Rai, Darla Pickett, Renee Massey, Neha Das Gupta, Subodh Selukar, Salem M. Akel, Leigh Poston, Yan Zheng, Ella Sorani, Irit Gliko Kabir, Mitchell J Weiss, Stephen Gottschalk, Julie Kanter, Matthew Hsieh, John Tisdale

Blood (2024) 144 (Supplement 1): 2100.1.

https://doi.org/10.1182/blood-2024-200330

Published: 2024

Journal Articles

Short-Term Costs Associated with Outpatient Use of Axicabtagene Ciloleucel in Second-Line Relapsed/Refractory Large B-Cell Lymphoma Based on Zuma-24 Clinical Trial

Olalekan O. Oluwole, Sally W. Wade, Nathaniel J Smith, Tomas Spousta, Jenny J. Kim, Yan Zheng, Timothy Best, Markqayne Ray, Lori A. Leslie

Blood (2024) 144 (Supplement 1): 7607.

https://doi.org/10.1182/blood-2024-206879

Published: 2024

Journal Articles

Impact of Duffy-Null Phenotype on Neutrophil Counts and Clinical Outcomes in Patients with Sickle Cell Disease and without Hydroxyurea

Yan Zheng, Jeffery Gossett, Guolian Kang, Pei-Lin Chen, Clifford M. Takemoto

Blood (2024) 144 (Supplement 1): 1129.

https://doi.org/10.1182/blood-2024-198232

Published: 2024

Journal Articles

Identification of Breakpoints of RHD Hybrid Alleles By Long-Read Sequencing

Ti-Cheng Chang, Jing Yu, Bensheng Ju, Melanie Loyd, Granger Ridout, Geoffrey A.M. Neale, Jane S Hankins, Mitchell J Weiss, Gorka Ochoa, Sunitha Vege, Stella T. Chou, John Easton, Yan Zheng

Blood (2024) 144 (Supplement 1): 4031.

https://doi.org/10.1182/blood-2024-198223

Published: 2024

Journal Articles

Duffy-Null Patients with Sickle Cell Disease Are at Risk for Low Neutrophil Counts with HU Treatment

Yan Zheng, Pei-Lin Chen, Jeffery Gossett, Guolian Kang, Clifford M Takemoto

Blood (2023) 142 (Supplement 1): 1125.

https://doi.org/10.1182/blood-2023-182459

Published: 2023

Journal Articles

Optimization of RH Genotyping from Whole Exon Sequencing Data By Machine Learning

Ti-Cheng Chang, Jing Yu, Zhaoming Wang, Jane S Hankins, Mitchell Weiss, Gang Wu, Connie M. Westhoff, Sunitha Vege, Stella Chou, Yan Zheng

Blood (2023) 142 (Supplement 1): 4034.

https://doi.org/10.1182/blood-2023-182089

Published: 2023

Journal Articles

Curative Potential of Axicabtagene Ciloleucel (Axi-Cel): An Exploratory Long-Term Survival Assessment in Patients with Refractory Large B-Cell Lymphoma from ZUMA-1

Sattva S. Neelapu, Caron A. Jacobson, Armin Ghobadi, David B. Miklos, Lazaros J. Lekakis, Clare Spooner, Jenny J. Kim, Harry Miao, Allen Xiaodong Xue, Yan Zheng, Frederick L. Locke

Blood (2023) 142 (Supplement 1): 4864.

https://doi.org/10.1182/blood-2023-174288

Published: 2023

Journal Articles

Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma

Blood (2023) 141 (19): 2307–2315.

https://doi.org/10.1182/blood.2022018893

Published: 2023

Includes: Supplemental data

Journal Articles

IL-13/IL-4 signaling contributes to fibrotic progression of the myeloproliferative neoplasms

Johanna Melo-Cardenas, Lavanya Bezavada, Jeremy Chase Crawford, Sandeep Gurbuxani, Anitria Cotton, Guolian Kang, Jeffrey Gossett, Christian Marinaccio, Rona Weinberg, Ronald Hoffman, Anna Rita Migliaccio, Yan Zheng, Marta Derecka, Ciro R. Rinaldi, John D. Crispino

Blood (2022) 140 (26): 2805–2817.

https://doi.org/10.1182/blood.2022017326

Published: 2022

Includes: Supplemental data

Journal Articles

Treatment of Individuals with Severe Sickle Cell Disease with OTQ923, an Autologous, Ex Vivo , CRISPR/Cas9-Edited, CD34+ Hematopoietic Stem and Progenitor Cell Product, Leads to Durable Engraftment and Fetal Hemoglobin Induction

Akshay Sharma, Jaap Jan Boelens, Maria I. Cancio, Jane Hankins, Prafulla A Bhad, Andrew Lewandowski, Xiaojun Zhao, Shripad Chitnis, Radhika Peddinti, Yan Zheng, Neena Kapoor, Fabio Ciceri, Jianping Yuan, Vionnie W. Yu, Susan C. Stevenson, Serena De Vita, James LaBelle

Blood (2022) 140 (Supplement 1): 1906–1908.

https://doi.org/10.1182/blood-2022-166254

Published: 2022

Journal Articles

ZUMA-8: A Phase 1 Study of KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia

Matthew S. Davids, Saad S. Kenderian, Ian W. Flinn, Brian T. Hill, Michael Maris, Paolo Ghia, Michael Byrne, Nancy L. Bartlett, John M. Pagel, Yan Zheng, Justyna Kanska, Wangshu Zhang, Behzad Kharabi Masouleh, Enrique Granados, Javier Pinilla Ibarz

Blood (2022) 140 (Supplement 1): 7454–7456.

https://doi.org/10.1182/blood-2022-167868

Published: 2022

Journal Articles

Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-up of ZUMA-1 Cohort 6

Blood (2022) 140 (Supplement 1): 10399–10401.

https://doi.org/10.1182/blood-2022-156117

Published: 2022

Journal Articles

SC-gtCAR19, a Non-Viral Genome Targeting Anti-CD19 CAR-T Candidate in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia: Updated Results from Long-Term Follow-up

Hui Wang, Ying Gao, Ding Zhang, Yan Zheng, Xingxing Hu, Qiuying Gao, Ben Niu, Limin Hou, Ling Wang, Weihua Zhang, Yi Zhang, Xingli Ru, Le Li, Zuohan Peng, Yi Wang

Blood (2022) 140 (Supplement 1): 4623–4624.

https://doi.org/10.1182/blood-2022-159871

Published: 2022

Journal Articles

Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): One-Year Follow-up of ZUMA-1 Cohort 6 (C6)

Blood (2021) 138 (Supplement 1): 2832.

https://doi.org/10.1182/blood-2021-147403

Published: 2021

Journal Articles

Optimization of Autologous Hematopoietic Progenitor Stem Cell Apheresis Collection from Plerixafor-Mobilized Patients with Sickle Cell Disease

Blood (2021) 138 (Supplement 1): 1770.

https://doi.org/10.1182/blood-2021-146669

Published: 2021

Journal Articles

A Preliminary Study on the Safety and Efficacy of a Novel Human BCMA-Targeting CAR-T Therapy in Patients with Relapsed/Refractory Multiple Myeloma

Yi Wang, Ying Gao, Hui Wang, Ding Zhang, Yan Zheng, Xingxing Hu, Qiuying Gao, Ben Niu, Hong Zhang, Wei Zhou, Weihua Zhang, Xingli Ru, Fangyuan Wang

Blood (2021) 138 (Supplement 1): 1735.

https://doi.org/10.1182/blood-2021-152651

Published: 2021

Journal Articles

Long-Term (≥4 Year and ≥5 Year) Overall Survival (OS) By 12- and 24-Month Event-Free Survival (EFS): An Updated Analysis of ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Refractory Large B-Cell Lymphoma (LBCL)

Blood (2021) 138 (Supplement 1): 1764.

https://doi.org/10.1182/blood-2021-148078

Published: 2021

Journal Articles

Clinical Features and Cytoreduction Therapy in Children with Newly Diagnosed Acute Myeloid Leukemia and Hyperleukocytosis

Georgios E. Christakopoulos, Kendra N Walker, Lei Wang, Clifford Takemoto, Yan Zheng, Ching-Hon Pui, Raul C Ribeiro, Stanley B Pounds, Jeffrey E. Rubnitz, Hiroto Inaba

Blood (2021) 138 (Supplement 1): 2295.

https://doi.org/10.1182/blood-2021-151045

Published: 2021

Journal Articles

A Feasibility and Safety Study of Non-Viral Genome Targeting Anti-CD19 CAR-T in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Yi Wang, MD, Hui Wang, Master, Ying Gao, PhD, Ding Zhang, Bachelor, Yan Zheng, MD, Xingxing Hu, Master, Qiuying Gao, Master, Zuohan Peng, PhD, Le Li, Ben Niu, Master, Limin Hou, Master, Ling Wang, Bachelor, Weihua Zhang, Bachelor, Yi Zhang, Bechelor, Xingli Ru, Bachelor

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-139190

Published: 2020

Journal Articles

Accurate Prediction of RH Genotypes Using Whole Genome Sequencing Data

Yan Zheng, MD PhD, Ti-Cheng Chang, PhD, Gang Wu, PhD, Jane S. Hankins, MD MS, Mitchell J. Weiss, MD PhD, Connie M. Westhoff, PhD, Stella T. Chou, MD

Blood (2018) 132 (Supplement 1): 2332.

https://doi.org/10.1182/blood-2018-99-119681

Published: 2018

NARROW

Motixafortide for Hematopoietic Stem and Progenitor Cell Mobilization and Collection in Sickle Cell Disease

Short-Term Costs Associated with Outpatient Use of Axicabtagene Ciloleucel in Second-Line Relapsed/Refractory Large B-Cell Lymphoma Based on Zuma-24 Clinical Trial

Impact of Duffy-Null Phenotype on Neutrophil Counts and Clinical Outcomes in Patients with Sickle Cell Disease and without Hydroxyurea

Identification of Breakpoints of RHD Hybrid Alleles By Long-Read Sequencing

Duffy-Null Patients with Sickle Cell Disease Are at Risk for Low Neutrophil Counts with HU Treatment

Optimization of RH Genotyping from Whole Exon Sequencing Data By Machine Learning

Curative Potential of Axicabtagene Ciloleucel (Axi-Cel): An Exploratory Long-Term Survival Assessment in Patients with Refractory Large B-Cell Lymphoma from ZUMA-1

Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma

IL-13/IL-4 signaling contributes to fibrotic progression of the myeloproliferative neoplasms

Treatment of Individuals with Severe Sickle Cell Disease with OTQ923, an Autologous, Ex Vivo , CRISPR/Cas9-Edited, CD34+ Hematopoietic Stem and Progenitor Cell Product, Leads to Durable Engraftment and Fetal Hemoglobin Induction

ZUMA-8: A Phase 1 Study of KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia

Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-up of ZUMA-1 Cohort 6

SC-gtCAR19, a Non-Viral Genome Targeting Anti-CD19 CAR-T Candidate in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia: Updated Results from Long-Term Follow-up

Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): One-Year Follow-up of ZUMA-1 Cohort 6 (C6)

Optimization of Autologous Hematopoietic Progenitor Stem Cell Apheresis Collection from Plerixafor-Mobilized Patients with Sickle Cell Disease

A Preliminary Study on the Safety and Efficacy of a Novel Human BCMA-Targeting CAR-T Therapy in Patients with Relapsed/Refractory Multiple Myeloma

Long-Term (≥4 Year and ≥5 Year) Overall Survival (OS) By 12- and 24-Month Event-Free Survival (EFS): An Updated Analysis of ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Refractory Large B-Cell Lymphoma (LBCL)

Clinical Features and Cytoreduction Therapy in Children with Newly Diagnosed Acute Myeloid Leukemia and Hyperleukocytosis

A Feasibility and Safety Study of Non-Viral Genome Targeting Anti-CD19 CAR-T in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Accurate Prediction of RH Genotypes Using Whole Genome Sequencing Data

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only